Literature DB >> 22727179

Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.

Martino Martinelli1, Sérgio Freitas de Siqueira, Eduardo Back Sternick, Anis Rassi, Roberto Costa, José Antônio Franchini Ramires, Roberto Kalil Filho.   

Abstract

Assessing the efficacy of implantable cardioverter-defibrillators (ICD) in patients with Chagas' heart disease (ChHD) and identifying the clinical predictors of mortality and ICD shock during long-term follow-up. ChHD is associated with ventricular tachyarrhythmias and an increased risk of sudden cardiac death. Although ChHD is a common form of cardiomyopathy in Latin American ICD users, little is known about its efficacy in the treatment of this population. The study cohort included 116 consecutive patients with ChHD and an ICD implanted for secondary prevention. Of the 116 patients, 83 (72%) were men; the mean age was 54 ± 10.7 years. Several clinical variables were tested in a multivariate Cox model for predicting long-term mortality. The average follow-up was 45 ± 32 months. New York Heart Association class I-II developed in 83% of patients. The mean left ventricular ejection fraction was 42 ± 16% at implantation. Of the 116 patients, 58 (50%) had appropriate shocks and 13 (11%) had inappropriate therapy. A total of 31 patients died (7.1% annual mortality rate). New York Heart Association class III (hazard ratio [HR] 3.09, 95% confidence interval 1.37 to 6.96, p = 0.0064) was a predictor of a worse prognosis. The left ventricular ejection fraction (HR 0.972, 95% confidence interval 0.94 to 0.99, p = 0.0442) and low cumulative right ventricular pacing (HR 0.23, 95% confidence interval 0.11 to 0.49, p = 0.0001) were predictors of better survival. The left ventricular diastolic diameter was an independent predictor of appropriate shock (HR 1.032, 95% confidence interval 1.004 to 1.060, p = 0.025). In conclusion, in a long-term follow-up, ICD efficacy for secondary sudden cardiac death prevention in patients with ChHD was marked by a favorable annual rate of all-cause mortality (7.1%); 50% of the cohort received appropriate shock therapy. New York Heart Association class III and left ventricular ejection fraction were independent predictors of worse prognosis, and low cumulative right ventricular pacing defined better survival.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22727179     DOI: 10.1016/j.amjcard.2012.05.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Chagas Heart Failure in Patients from Latin America.

Authors:  Reinaldo B Bestetti
Journal:  Card Fail Rev       Date:  2016-11

2.  Chagas heart disease: A contemporary review.

Authors:  Alejandro Velasco; Carlos A Morillo
Journal:  J Nucl Cardiol       Date:  2018-07-18       Impact factor: 5.952

Review 3.  Treatment of Chagas cardiomyopathy.

Authors:  Fernando A Botoni; Antonio Luiz P Ribeiro; Carolina Coimbra Marinho; Marcia Maria Oliveira Lima; Maria do Carmo Pereira Nunes; Manoel Otávio C Rocha
Journal:  Biomed Res Int       Date:  2013-11-24       Impact factor: 3.411

4.  Seven years of use of implantable cardioverter-defibrillator therapies: a nationwide population-based assessment of their effectiveness in real clinical settings.

Authors:  Arn Migowski; Antonio Luiz Ribeiro; Marilia Sá Carvalho; Vitor Manuel Pereira Azevedo; Rogério Brant Martins Chaves; Lucas de Aquino Hashimoto; Carolina de Aquino Xavier; Regina Maria de Aquino Xavier
Journal:  BMC Cardiovasc Disord       Date:  2015-03-13       Impact factor: 2.298

5.  Clinical Course After Cardioverter-Defibrillator Implantation: Chagasic Versus Ischemic Patients.

Authors:  Francisca Tatiana Moreira Pereira; Eduardo Arrais Rocha; Marcelo de Paula Martins Monteiro; Neiberg de Alcantara Lima; Carlos Roberto Martins Rodrigues Sobrinho; Roberto da Justa Pires Neto
Journal:  Arq Bras Cardiol       Date:  2016-07-11       Impact factor: 2.000

6.  Chagas Disease-induced Sudden Cardiac Arrest.

Authors:  Michael M Neeki; Michelle Park; Karan Sandhu; Kathryn Seiler; Jake Toy; Massoud Rabiei; Sasikanth Adigoupula
Journal:  Clin Pract Cases Emerg Med       Date:  2017-10-09

7.  Amiodarone for arrhythmia in patients with Chagas disease: A systematic review and individual patient data meta-analysis.

Authors:  Cinara Stein; Celina Borges Migliavaca; Verônica Colpani; Priscila Raupp da Rosa; Daniel Sganzerla; Natalia Elis Giordani; Sandro Renê Pinto de Sousa Miguel; Luciane Nascimento Cruz; Carisi Anne Polanczyk; Antonio Luiz P Ribeiro; Maicon Falavigna
Journal:  PLoS Negl Trop Dis       Date:  2018-08-20

Review 8.  Sudden Cardiac Death Risk Stratification and Prevention in Chagas Disease: A Non-systematic Review of the Literature.

Authors:  Roberto Keegan; Cynthia Yeung; Adrian Baranchuk
Journal:  Arrhythm Electrophysiol Rev       Date:  2020-12

9.  Epicardial ablation for ventricular tachycardia in chronic Chagas heart disease.

Authors:  Mauricio Scanavacca
Journal:  Arq Bras Cardiol       Date:  2014-06       Impact factor: 2.000

10.  Long-term follow-up of patients with chronic chagas disease and implantable cardioverter-defibrillator.

Authors:  Francisca Tatiana Moreira Pereira; Eduardo Arrais Rocha; Marcelo de Paula Martins Monteiro; Almino Cavalcante Rocha Neto; Elisabeth de Francesco Daher; Carlos Roberto Martins Rodrigues Sobrinho; Roberto da Justa Pires Neto
Journal:  Pacing Clin Electrophysiol       Date:  2014-01-27       Impact factor: 1.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.